Abbott Laboratories: The 2013 Drop That Was Not a Dividend Cut
Market figures in this article reflect the data snapshot available on August 13, 2026 and are not updated afterward.
Live Data Dashboard
View ABT — price, yield, current profile & charts
Two Things in Abbott's Data That Look Wrong
Abbott's dividend history table has a row that stops most readers: 2013, down 41.7%. The year before it, the annual dividend was $0.96 a share. In 2013 it was $0.56. A drop that size in a single year is the classic signature of a company in trouble.
Abbott was not in trouble, and it did not cut its dividend. Meanwhile the same page reports a 53-year raise streak, a Current Profile of Review, dividend growth of +6.9% over the last twelve months, and a valuation tagged Undervalued. Four readings pointing in four directions. Both of these — the 2013 row and the Review label — have specific, checkable explanations, and neither is what it looks like at a glance.
What the 2013 Row Actually Records
On January 1, 2013, Abbott completed the separation of AbbVie, spinning its research-based pharmaceuticals business into a standalone public company. Shareholders kept their Abbott shares and received AbbVie shares alongside them. The income did not shrink; it split across two tickers.
A dividend history table cannot see that. It tracks payments made by one ticker, so when roughly half the business walks out the door, the remaining company's per-share dividend falls with it. The table records what Abbott paid. It has no way to record what the same investor collected from AbbVie in the same year.
This is why a single red row in a dividend history is weak evidence on its own. The 2014 row makes the point from the other side: +57.1%, a figure no ordinary company posts. Neither number describes a normal operating year. Together they mark a corporate restructuring, and the way to confirm that is the filings rather than the chart — Abbott's separation documents are on SEC EDGAR.
The broader pattern is common enough to be worth expecting. Spin-offs, mergers and payment-schedule changes all leave marks in a per-share dividend series that look exactly like distress, which is one reason a year-over-year decline is such an unreliable warning signal on its own — a point developed in Before a Dividend Is Cut.
How a Streak Survives a Halved Payment
If Abbott's per-share dividend fell 41.7%, how is the raise streak 53 years?
Because the streak is measured against the shareholder's total position, not against one ticker's payment line. The convention among dividend-record keepers is that a spin-off does not break a streak when the combined dividend from the parent and the spun-off company is maintained or increased. Abbott is treated as having kept raising through 2013 on that basis, and the Dividend Kings list reflects it.
The tension is real, though, and it is worth naming rather than smoothing over. The per-share series and the streak count are measuring two different things. An investor who bought Abbott in 2014 and never held AbbVie experienced a dividend that started from the reduced base. The 53-year label describes the continuity of a policy, not the experience of every holder.
Why the Profile Reads Review
The second oddity is the Current Profile. Abbott shows Review, the label applied when a company shows a dividend decline, elevated payout context, or irregular growth data relative to its tier. Nothing about Abbott's growth is irregular: the trailing twelve months show +6.9%, and the long-run compound rate across 2011–2025 is +7.1% a year.
The trigger is coverage. Abbott's payout ratio is 80.3%, and the threshold that separates comparable coverage from elevated coverage sits at 80%. Abbott is three-tenths of a point over the line. The methodology behind that classification is set out on the About page.
That is worth sitting with, because it cuts both ways. A label that flips on a third of a percentage point is not making a strong claim about Abbott specifically — it is reporting that the company has crossed into the range where coverage deserves a look. It also means the label will move on ordinary earnings noise. The reading to take from it is not "something is wrong" but "the cushion is thinner than the record suggests."
| Metric | Abbott (ABT) | King median |
|---|---|---|
| Dividend yield | 2.24% | 2.28% |
| Payout ratio | 80.3% | 58.4% |
| Consecutive raise years | 53 | 54 |
Against the tier, Abbott is unremarkable on yield and record and clearly heavier on coverage — 22 points above the median King. That single line explains the Review tag better than any other number on the page. What the ratio does and does not settle is covered in The Payout Ratio.
Where This Reading Can Be Wrong
Two cautions belong here.
First, the payout ratio is computed from trailing GAAP earnings, and trailing GAAP earnings break in predictable ways. A large impairment or restructuring charge collapses reported profit while the dividend keeps running, and the resulting ratio overstates strain. This site marks the worst of those cases as n/m rather than printing a number; Abbott is not one of them, so 80.3% stands as a real figure. But the mechanism — described in When the Payout Ratio Breaks — is a reminder that one year's ratio is a snapshot of accounting, not a measure of cash generation.
Second, the spin-off explanation for 2013 does not mean every sharp decline in a dividend history is benign. It means the table alone cannot tell the difference. The check is always the same: find the corporate event, or find the earnings deterioration. One of them will be there.
What Would Change the Reading
The number worth tracking is coverage, not the streak. A payout drifting further above 80% while growth decelerates would turn a borderline label into a substantive one. A payout easing back under the line, with growth holding near its 7.1% long-run rate, would move the profile without anything about the business having changed.
Neither the 2013 row nor today's Review tag is the story a first glance suggests. The screener is the place to see how many other Kings currently sit on the wrong side of the same 80% line.
Disclaimer: This is informational only and not financial advice. Figures reflect the site snapshot dated 2026-08-13 and move with the market. Investing carries risk of loss, including loss of principal.